John Fleischman

John Fleischman

John is ASCB Senior Science Writer and the author among other things of two nonfiction books for older children, "Phineas Gage: A Gruesome But True Story About Brain Science" and "Black & White Airmen," both from Houghton-Mifflin-Harcourt, Boston.

Thursday, 20 March 2014 10:45

Far Afield—An ORCID By Any Other Name

It's not a corsage but ORCID is a way of pinning your scientific identity firmly to your scientific chest. ORCID is, of course, an acronym. It stands for Open Researcher and Contributor ID but ORCID is also the tiny organization with global reach that issues unique alphanumeric identifiers for contributors to the world's scholarly and scientific literature. ORCID, the organization, refers to the identifier as the ORCID ID, which both makes sense and sounds redundant. As children, we all believe that we are what the British call a "one off" because it's self-evident that there is only one you, even if "you" are half a set of twins or have a common surname like Wang, Kim, Smith, Garcia, Müller, Murphy, or Rossi. But in research, convincing the wider world that you are THE one who published THIS paper is not trivial. Thus comes ORCID: one researcher, one 16-digit number (that is also a unique URL).

The University of Chicago (UChicago) and the Marine Biological Laboratory (MBL) have made their first joint research award since MBL became a UChicago affiliate last year to a group headed by ASCB member Clare Waterman with three other ASCB members as co-investigators. The Frank R. Lillie Research Innovation Award will support cross-disciplinary research at MBL in Woods Hole, MA, into integrin activation and actin dynamics during cell migration. The $125,000 award honors both MBL's 125th anniversary and Frank Lillie, who was chair of Zoology at UChicago and the second director of MBL in the early 20th century.

It's Thanksgiving. You're home from grad school and lab where you're fired up about cytoplasmic accumulation and nuclear clearance of TDP-43, a protein implicated in amyotrophic lateral sclerosis, when Aunt Carol passes you the candied sweet potatoes and sweetly asks, "Now, dear, what is it that you are doing in your research?" You take a deep breath and begin, "So..." About a minute later, you're explaining how to knock out the TDP-43 analog in fruit flies when a look of horror crosses Aunt Carol's face. "Flies? Your laboratory is full of flies?"

March is Women's History Month and both the Royal Society in the United Kingdom and the Smithsonian Institution Archives (SI Archives) in the United States scheduled Wikipedia "edit-a-thon" sessions to strengthen the online encyclopedia's inadequate coverage of women in science history. The Royal Society's event was last week but for the Smithsonian's there's still time to sign up and learn how to become a Wiki editor or go along in person to the Women In Science session on Tuesday, March 18, at the SI Archives offices in Washington.

ASCB member, former ASCB President, and 2013 ASCB Annual Meeting keynote speaker, Elaine Fuchs has been named the winner of the American Association for Cancer Research's 2014 Pezcoller Foundation-AACR International Award for Cancer Research. Fuchs, who is a professor at the Rockefeller University and a Howard Hughes Medical Institute investigator, is known for her pioneering work on epidermal stem cells and the relationship between "stemness" and cancer progression.

One of the pleasures of the AAAS Annual Meeting is walking through walls. Science can be a windowless warren if you stick with what you know so sometimes it pays to step out. At AAAS, you can seek out a symposium on some outlandish topic just to view unknown terrain. Sometimes you glimpse far horizons. Sometimes you are fogged in.

CHICAGO—The "Triple A-S" meeting is like no other scientific gathering in that it is not really for scientists but for journalists who follow science. Scientists do come to present talks or to serve on AAAS governing sections, but to understand the meeting's central purpose, think of AAAS as the world's largest annual science press conference.

John Pringle has been going to different sorts of meetings this last decade. He is still a regular at the ASCB Annual Meeting and at smaller yeast biology gatherings. Indeed he was in New Orleans for the ASCB Annual Meeting in December to receive the E.B. Wilson Medal, the ASCB's highest scientific honor, for his pioneering work on cell polarization and cytokinesis. But Pringle also goes, when he can, to the International Coral Reef Symposium, the Society for Microbial Ecology, and the International Symbiosis Society. He still has a small yeast group in his lab although his other interests have represented the majority since 2007. He is becoming known at these marine biology and ecology meetings, but Pringle says that he wishes there were more cell biologists there. John Pringle aims to correct that.

It was either serendipity or the anxiety of an entire generation of graduate students coming to a boil, but last fall something triggered an explosion of science advocacy on the Emory University campus in Atlanta. A grad student "advocacy journal club" has sprung to life with 50 members, ambitious plans for organizing more, and a working alliance with the dean and with Emory's Office of Governmental Affairs.

NIH Director Francis Collins yesterday unveiled an unusual open access alliance of 10 "biopharmaceutical" companies and eight nonprofits to wade through the growing flood of bio data on four diseases—Alzheimer's, Type 2 diabetes, and the autoimmune disorders, rheumatoid arthritis and lupus—to identify therapeutic targets and characterize biomarkers. All data and analyses will be publicly shared. The pharma and nonprofit allies will put up $230 million over five years in hopes of making translational sense of the mass of new imaging, "omic" sequencing, and other data on these four diseases with massive impacts on public health. The new alliance is called the Accelerating Medicines Partnership (AMP).